Welcome to

HEART FAILURE/TRANSPLANT

FELLOWSHIP PROGRAM

Welcome to Cardiology and Electrophysiology

Nasir Sulemanjee, MD, FACC, Program Director

Welcome

Aurora Heart Failure & Transplant Cardiology Fellowship Program

Shadow Line

Nasir Sulemanjee, MD, FACC

Nasir Sulemanjee, MD, is a board-certified cardiologist with additional expertise in treating patients with heart failure. He has extensive training in diseases of the heart and blood vessels, with particular expertise in advanced heart failure, mechanical assist devices and cardiac transplantation.

Medical education:
Aga Khan University Medical College (Degree earned: MBBS) Graduated in 1999.
.
Residencies:
Internal Medicine (3 years) - University of Texas Medical Branch
.
Fellowships:
Cardiovascular Disease (3 years) & Advanced Heart Failure and Transplant (1 year) - University of Texas Medical Branch

We invite you to become acquainted with our ACGME accredited fellowship program in the subspecialties of Advanced Heart Failure and Transplant Cardiology. We will introduce our program, our directors and faculty members, describe our clinical and laboratory facilities, and tell you what it's like to live and work in Milwaukee.

Aurora St. Luke's Medical Center has a long tradition of excellence in the field of heart failure, pulmonary hypertension, mechanical circulatory support devices and cardiac transplantation. We have the largest clinical population of heart failure and pulmonary hypertension in the state of Wisconsin, with the largest number of ongoing clinical trials in this region. There has been over 600 LVADs implanted, since inception of the LVAD program in 1986, with an average of 40-60 implants per year in the past few years. There also has been over 800 heart transplants performed at Aurora St. Luke's Medical Center since 1984, with an average of 25-35 transplants every year for the past few years. This makes Aurora St. Luke's Medical Center the largest transplant and VAD program in the state of Wisconsin. We also have excellent outcomes, with > 95% 1-yr survival of cardiac transplant and > 85% 1-yr survival following LVAD implantation, both of which are above national standards.